tiprankstipranks
Company Announcements

Kazia Therapeutics Advances Cancer Drug Development with Strategic Moves and Promising Trial Results

Story Highlights
  • Kazia Therapeutics is advancing its cancer drug candidates, paxalisib and EVT-801, through promising clinical trials.
  • The company delisted from ASX to focus on NASDAQ, aiming to enhance capital-raising capabilities for its drug development plans.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Kazia Therapeutics Advances Cancer Drug Development with Strategic Moves and Promising Trial Results

Kazia Therapeutics ( (KZIA) ) has shared an update.

Kazia Therapeutics released its Annual Report for the fiscal year ending June 30, 2024, highlighting significant progress in its drug development programs. The company has made strides with its lead asset, paxalisib, receiving Fast Track Designation from the FDA and showing promising clinical results in trials for brain metastases and other cancers. Additionally, Kazia’s strategic decision to delist from the ASX and focus on NASDAQ aims to enhance its capital-raising capabilities. The company also reported successful completion of a Phase 1 trial for EVT-801, targeting advanced solid tumors, with encouraging results particularly in ovarian cancer. These developments position Kazia to potentially improve patient outcomes and expand its market presence.

More about Kazia Therapeutics

Kazia Therapeutics is a biotechnology company focused on developing innovative cancer therapies. The company is advancing two primary drug candidates, paxalisib and EVT-801, through various clinical trials aimed at addressing unmet needs in cancer care.

YTD Price Performance: -43.74%

Average Trading Volume: 2,072,598

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $5.02M

Learn more about KZIA stock on TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App